Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1702 : SLVL  update : 2022/04/18
CommentHuman cell line derived from splenic B cell lymphoma.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Inokuchi, Koiti
Originator Inokuchi, Koiti
Year of deposit 2000
Another name VL51
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 70 years
Tissue spleen
Disease name spleuic lymphoma
Classification cancer
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_3169
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Animal PCR OK
Virus (HIV) LT 400
Virus (HTLV-1) (-)
Isozyme LD, NP
Chromosome mode 75-82(50) : /77(3),78(10),79(7),80(11),81(11),82(6)
STR(human) OK
Reference information Reference 1
User's Publication 5


To topTop
Reference
3139  Inokuchi K, Abo J, Takahashi H, Miyake K, Inokuchi S, Dan K, Nomura T  Establishment and characterization of a villous lymphoma cell line from splenic B-cell lymphoma.  Leuk Res  1995  19:817-22  PubMed ID: 8551798   DOI: 10.1016/0145-2126(95)00059-3

To topTop
User's Publication
16945  Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.  Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy  Cancer Sci  2022  113(6):2129-2143  PubMed ID: 35343027   DOI: 10.1111/cas.15349
11433  Chiu H, Trisal P, Bjorklund C, Carrancio S, Toraño EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, Delfau-Larue MH, Morschhauser F, Ramsay AG, Gandhi AK.  Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.  Br. J. Haematol.  2019    PubMed ID: 30767211   DOI: 10.1111/bjh.15797
10269  Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.  Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages  J Clin Exp Hematop  2017  57:15-20  PubMed ID: 28420814   DOI: 10.3960/jslrt.17003
13994  Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y.  An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma  Cancer Sci  2016  107(11):1696-1704  PubMed ID: 27564404   DOI: 10.1111/cas.13065
15339  Bai B, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Takeya M, Komohara Y.  Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study  J Clin Exp Hematop  2013  53(2):127-33  PubMed ID: 23995109   DOI: 10.3960/jslrt.53.127



Back Back Return Top Page